james daniel campbell, m.d., m.s. - university of maryland ... · james daniel campbell, m.d., m.s....

James Daniel Campbell, M.D., M.S.

2

Ethics 2014 Intensive Bioethics Course. Georgetown University. Five-day immersion course

in bioethics, both philosophical underpinnings and case studies. (June 2-6, 2014) Certifications 1992 Diplomate, National Board of Medical Examiners 1994 Diplomate, American Board of Pediatrics 1991 Provider, Advanced Trauma Life Support 1994 Instructor, Pediatric Advanced Life Support 1994 Instructor, Neonatal Resuscitation Program 2001 Board Certification, Pediatric Infectious Diseases, American Board of Pediatrics 2002 Recertification, General Pediatrics, American Board of Pediatrics Medical Licensures 1993 Active Maryland Medical License 1995 Inactive Guam Medical License 2010 Inactive Uganda Medical License Military Service 1987-1991 Health Professions Scholarship Program, U.S. Navy

Rank of Ensign Columbia University College of Physicians and Surgeons

New York, New York 1991-1998 Active Duty Officer, U.S. Navy Ranks of Lieutenant to Lieutenant Commander Pediatrician Stationed in Bethesda, Maryland, and on Guam, Micronesian Islands 1998-2006 Reserve Officer, U.S. Navy Highest rank attained: Commander (05) Honorable Discharge


3

Employment History Academic Appointments: 1996-1998 Assistant Professor of Pediatrics, Uniformed Services University of the Health

Sciences (USUHS) 1998-2006 Assistant Professor of Pediatrics (Volunteer), USUHS 2001-2007 Assistant Professor of Pediatrics, University of Maryland School of Medicine 2007-2015 Associate Professor of Pediatrics, University of Maryland School of Medicine (leave of absence, August, 2007- August, 2012, while working for the Centers for

Disease Control and Prevention in Uganda) 2015-present Professor of Pediatrics, University of Maryland School of Medicine Other Employment: 2007-2012 Medical Officer/Epidemiologist Centers for Disease Control and Prevention (CDC), Atlanta, GA Global AIDS Program (GAP) and Division of HIV/AIDS Prevention (DHAP) Kampala and Entebbe, Uganda Professional Society Memberships 1991 Member, Alpha Omega Alpha (AOA) Honor Medical Society 1994 Member, Uniformed Section, American Academy of Pediatrics 1994 Candidate Fellow, American Academy of Pediatrics 1998 Fellow, American Academy of Pediatrics 1998 Member, Section on Infectious Diseases, American Academy of Pediatrics 1998 Member, Pediatric Infectious Disease Society 1998 Member, Infectious Diseases Society of America 2014 Member, Public Responsibility in Medicine and Research Honors and Awards 1983 Valedictorian, St. Pius X Preparatory Seminary (high school) 1987 Magna Cum Laude, Georgetown University (undergraduate) 1991 Alpha Omega Alpha Honor Medical Society (medical school) 1991 The William Perry Watson Prize for Outstanding Student in Pediatrics Columbia University College of Physicians and Surgeons (awarded to the single graduating student with the highest honors in Pediatrics) 1991 The Marie Nercessian Memorial Award for Outstanding Student in the

Compassionate Care of Patients, Columbia University College of Physicians and


4

Surgeons (awarded to the single graduating student displaying exemplary compassion for patients)

1994 Outstanding Pediatric Teacher for Medical Students, Uniformed Services University of the Health Sciences (awarded to the Pediatrics resident voted the best teacher of Pediatrics by third and fourth year medical students)

1996 Navy Commendation Medal (for accomplishments as Director of the Pediatric Department, Director of the

Immunization Clinic, Chairman of the Infection Control Committee, and other duties performed at Guam Naval Hospital)

1997 Outstanding Pediatric Teacher, National Naval Medical Center and Walter Reed Army Medical Center Pediatric Residency Program (awarded to the single Pediatrics faculty member at either institution considered by the residents to be the best teacher)

1998 Outstanding Pediatric Teacher, National Naval Medical Center and Walter Reed Army Medical Center Pediatric Residency Program (same award as above, awarded two years in a row)

1998 Navy Commendation Medal (for accomplishments as Director of the General Pediatric Ambulatory Care Clinic, author of the General Pediatrics curriculum, among other duties performed at the National Naval Medical Center)

1999 Alexander J. Schaffer Teaching Award for Outstanding Contributions to Housestaff Education, Department of Pediatrics, University of Maryland Medical Center (voted by the housestaff as the single best teacher in Pediatrics, awarded during fellowship although previously only given to members of the faculty)

2004 Nomination, Maryland Immunization Excellence Award, Maryland Partnership for Prevention

2004 America’s Top Pediatricians Listing, Consumers’ Research Council of America 2009 U.S. Embassy Uganda, Meritorious Service Award for leadership in healthcare

research in Uganda 2011 U.S. Embassy Uganda, Franklin Award for participation in identifying an

outbreak of Yellow Fever in the north of Uganda 2012 Appreciation Award, The AIDS Support Organization (TASO), Kampala,

Uganda, for leadership in the Partners PrEP research study in Tororo and Mbale 2015 Baltimore’s Top Doctors. Named among best Pediatric Infectious Diseases

doctors by Baltimore Magazine, 2015. Clinical Activities Clinical Expertise: Pediatric Infectious Diseases, Tropical Medicine, Vaccines, Pediatrics, Newborn Care, HIV Scope of Clinical Practice: Clinical scope is described below.


5

1994-1996 Staff Pediatrician, Naval Hospital Guam (involved inpatient and outpatient care

of large panel of the children of U.S. Naval personnel) 1994-1996 Head, Pediatric Inpatient Services, Naval Hospital Guam (directed all inpatient

services for children at the hospital) 1995-1996 Staff Pediatrician, The Doctors Clinic, Taumuning, Guam (involved the care of a

panel of children in the community and night and weekend call for the practice) 1995-1996 Staff Pediatrician, Guam Memorial Hospital, Guam (involved inpatient care for

children from the civilian Guamanian community) 1996-1998 Staff Pediatrician, National Naval Medical Center; 1500 patient panel (provided

all pediatric care for a large cohort of children whose parents were stationed in and around Washington, D.C., including at Bethesda Naval Hospital, the NIH, the FDA, and elsewhere)

1996-1998 Attending Pediatrician, Full Term Nursery, 1 month per year, National Naval Medical Center (involved admission, care, and discharge of all newborns as well as teaching of all new parents)

1996-1998 Attending Physician, Pediatric Ward, 1 month per year, Walter Reed Army Medical Center (involved directing a team of residents and students in the care of all children admitted to the general pediatric ward service)

1998-1999 Clinical Fellow, Pediatric Infectious Diseases, University of Maryland Hospital for Children (involved responsibility for all inpatient and outpatient Pediatric Infectious Disease consultations, daily rounds, supervision of all rotating students [medical students, fellows, pharmacists], and presenting cases and relevant literature at a weekly conference)

2001-2007 Pediatric Infectious Disease Consult Service Attending Physician, 8 to 13 weeks per year, University of Maryland Hospital for Children (involved responsibility for all inpatient and outpatient consultations and the teaching of fellows, residents, and students; also involved frequent telephone consultation from providers throughout Maryland and the surrounding region)

2002-2007 Teaching or Clinical Attending, General Pediatric Service: 6 weeks every year. University of Maryland Hospital for Children (involved clinical care and/or teaching of residents and students)

2012- present Pediatric Attending, Full Term Nursery, University of Maryland Hospital for Children: 6-8 weeks plus 5 weekends per year (involves full service care for all newborns [about 35 per week] and the teaching of Pediatric and Family Medicine residents [2 or 3 per week], nurse practitioners [1], and third-year clerkship medical students [2], as well as physical exam skill sessions with rotating second-year medical students [5 to 10 per session])

2013-present Pediatric Infectious Disease Consult Service Attending Physician, 8 weeks per year, University of Maryland Hospital for Children (involves responsibility for all inpatient [about 1 to 4 per day] and outpatient [about 2 per week] consultations and the teaching of fellows [1], residents [typically 1 or 2], and students [typically


6

1 or 2]; also involves frequent telephone consultation from providers throughout Maryland and the surrounding region)

Administrative Service Institutional Service: National Naval Medical Center and Naval Hospital Guam 1994 Resident Member Residency Integration Committee National Naval Medical Center (successfully integrated the Pediatrics residency

programs of Bethesda Naval Hospital and Walter Reed Army Medical Center) 1995 Department Head, Department of Pediatrics, Naval Hospital Guam (supervised a

department of 4 pediatricians and many nurses, corpsmen, and support staff; directed the immunization clinic and the Pediatric inpatient, nursery, outpatient, and emergency services)

1994-1996 Head, Immunization Clinic, Naval Hospital Guam (supervised all immunizations provided to dependents of active duty military at the base)

1995-1996 Chairman, Infection Control Committee, Naval Hospital Guam (directed all infection control efforts at the hospital)

1994-1996 Vice Chairman, Family Advocacy Committee (the child physical and sexual abuse investigation committee for the military), Naval Hospital Guam (worked together with clinicians, social workers, law enforcement, and families to provide care and placement for potentially abused children of military personnel; also worked with the child abuse advocates for civilian children on Guam in standardizing approaches to evaluation)

1994-1996 Organizer, Guam Pediatric Journal Club (organized Pediatric providers in the military and civilian communities to discuss current literature)

1996 Command Joint Commission on Accreditation of Healthcare Organizations (JCAHO) Leader, Infection Control and Pediatrics, Naval Hospital Guam (responsible for preparations leading up to JCAHO inspection and for meeting with JCAHO auditors during accreditation visit; led to very high scores and accreditation for this remote hospital)

1994-1996 Member, Pharmacy and Therapeutics Committee, Naval Hospital Guam (represented Pediatrics in all formulary decisions)

1994-1996 Triage Officer, Disaster Drill Team, Naval Hospital Guam 1994-1998 Instructor, Pediatric Advanced Life Support (PALS), 4 times per year, Naval

Hospital Guam and National Naval Medical Center (provided free instruction in PALS to physicians, nurses, corpsmen [medics], and others)

1996-1998 Head, Pediatric Ambulatory Clinic, National Naval Medical Center (supervisor responsible for all outpatient care of children at Bethesda Naval Hospital)


7

1996-1998 Assistant Head, Pediatric Rheumatology Clinic, National Naval Medical Center (cared for all children with rheumatologic disorders referred to Bethesda Naval Hospital, under the supervision of the Navy’s sole Pediatric Rheumatologist, Dr. Ildy Katona)

1996-1998 Member, Pharmacy and Therapeutics Committee, National Naval Medical Center 1996-1998 Member, Animal Vector and Rabies Control Board, National Naval Medical

Center 1996-1998 Member, Pediatric Residency Curriculum Committee; Author, Outpatient

Curriculum and Continuity Clinic Curriculum, National Naval Medical Center (instrumental in re-vamping and later updating and editing the curriculum; designed all the standardized forms for well-child visits, and taught well-child care to all residents and students)

1996-1998 Coordinator, Pediatric Morning Report and Pediatric Attending Roundtable, National Naval Medical Center (supervised all resident presentations at morning report; initiated the “Roundtable,” a new teaching tool in which attending Pediatricians were posed difficult clinical dilemmas in front of the entire department)

1996-1998 Pediatric Department Liaison to the Immunization Clinic, National Naval Medical Center (assisted the central immunization clinic with issues related to childhood vaccinations)

1996-1998 Pediatric Department Liaison to the Child Development Center, National Naval Medical Center (wrote policy for the child care center and assisted with issues related to medical care of the attendees)

1996-1998 Faculty Advisor, Pediatric Residency (1 resident per year), National Naval Medical Center

University of Maryland School of Medicine (1998-2007) 1999-2001 Medical School Academic Council, Alternate Member, Department of Pediatrics,

University of Maryland School of Medicine 2001-2007 Interviewer, Pediatric Residency Program applicants, University of Maryland

School of Medicine (interviewed approximately 15 to 20 prospective Pediatrics interns per year)

2002-2007 Member, Executive Committee of the Infection Control Committee, University of Maryland Medical Systems (representing Pediatrics and Pediatric Infectious Diseases)

2002-2007 Member, Institutional Review Board, University of Maryland School of Medicine (provided Pediatric and Infectious Disease expertise for Committee 1 of the IRB, primary and secondary reviewer on multiple protocols per meeting)

2003-2007 Chairman, International Clinical Studies Group, Center for Vaccine Development, University of Maryland School of Medicine (coordinated investigators from Baltimore, Mali, Malawi, and Chile, assisted the International Regulatory Affairs specialist with writing and reviewing standard operating procedures for


8

international trials) 2005-2007 Member, Strategic Committee for University of Maryland School of Medicine

Bio-informatics Core (assisted the core leaders with long-term planning) 2005-2007 Member, Judicial Board, University of Maryland School of Medicine (deliberated

on honor code investigations among students and faculty); (rejoined the board in 2012, upon my return from Uganda)

2006-2007 Invited Guest Speaker, Internal Medicine Interest Group, University of Maryland School of Medicine (provide information about research, career opportunities, etc. to medical students interested in Internal Medicine)

2006-2007 Director, Pediatric Infectious Disease Fellowship, University of Maryland School of Medicine

Centers for Disease Control and Prevention (CDC), Uganda (2007-2012) 2007-2010 Area Associate Director of Science, Epidemiology Branch, CDC Uganda

(reviewed all abstracts, manuscripts, IRB submissions, other documents for a subset of projects in the branch)

2009-2010 Project Officer, Program Unit, CDC Uganda (oversaw projects performed by implementing partners in the President’s Emergency Plan for AIDS Relief [PEPFAR] program, providing technical and other oversight)

2011-2012 Associate Director of Science, CDC Uganda (reviewed all abstracts, manuscripts, IRB submissions, other documents for all science performed by CDC and its implementing partners in Uganda)

University of Maryland School of Medicine and UMB (2012-present) 2012-present Vice Chair, Executive Committee, Institutional Review Board, University of

Maryland, Baltimore (chair IRB meetings, review policy, perform expedited reviews, expertise in Pediatric and international regulatory issues; Investigational New Drug Applications [INDs])

2012-present Associate Director, Clinical Research Training and Mentoring Program, University of Maryland Baltimore, Human Research Protections Office (HRPO), Office of the President (assist faculty members with IRB submissions, design, reporting of human subject research)

2013-present Member, Ethics Advisory Committee, University of Maryland Medical Center (review clinical ethical cases in the hospital and institutional policies that involve ethical items)

2013-present Interviewer, University of Maryland School of Medicine, medical school applicant interviews and review of applications; 5-10 per year

2014 Member, Advisory Committee to the Department of Epidemiology and Preventive Medicine Masters in Clinical Research program

2014 Co-Chair, Ebola Information Network, University of Maryland Baltimore


9

Local and National/International Service Local Service: 1995-1996 Physician Member, Guam HIV Community Planning Group for the Centers for

Disease Control and Prevention 1995-1996 Medical Advisor, Civil Action Team, Kosrae, Federated States of Micronesia

(directed all medical care for military personnel involved in humanitarian work on Kosrae, such as building schools, roads, etc.; provided Pediatric care to ex-patriates and to Kosrae children during visits every few months)

2001-2007 Chairman, Committee on Infectious Diseases, Maryland State Chapter, American Academy of Pediatrics (member of the executive committee; acted as the state AAP spokesperson on issues of Infectious Diseases and vaccines before various groups, including the Department of Health and Mental Hygiene in the state of Maryland)

2002-2007 Member, Statewide Advisory Commission on Immunizations, State of Maryland, appointment by the Secretary of Department of Health and Mental Hygiene (represented the American Academy of Pediatrics; the commission advises the state on issues such as vaccine shortages, vaccine safety, school vaccine requirements, etc.)

2003-2007 Member, Infectious Disease Advisory Board, Baltimore City Health Department’s Office of Public Health, Preparedness, and Response (the board advises the city on issues of biopreparedness)

2005-2007 Member, State Commission on Lyme Disease Treatment and Prevention, organized by the Maryland Department of Health and Mental Hygiene (the commission advises practitioners in Maryland about tick-borne infections)

2005-2007 Maryland State immunization representative to the national office of the American Academy of Pediatrics

2006-2007 Co-author of a review of the scientific refutation of a relationship between thimerosal and autism on behalf of the President of the University of Maryland Baltimore. Presented to Delegate Hammen, Chair of the Maryland House Committee tasked with reviewing bills on this topic (December, 2006)

2007 Testified, together with Maryland Department of Health and Mental Hygiene, the county Health Officers, and the Baltimore City Commissioner of Health, on thimerosal and vaccines before members of the Maryland House and Senate (January 29, 2007)

2007 Subject Matter Expert, Interdisciplinary Symposium on Bio-Preparedness in the Washington Metropolitan Region, sponsored by the Middle Atlantic Regional Center of Excellence in Biodefense and Emerging Pathogens (NIH) and the Center for Health and Homeland Security at the University of Maryland School of Law; USUHS, Bethesda, MD (February 27, 2007)

2008-2012 Member, School Board, International School of Uganda, Lubowa, Uganda (elected position; tasked as Board of Governors for all financial and strategic


10

decisions at the school; Vice Chair 2009-2010; Chair of Institutional Advancement Committee 2009-2010; Chair 2010-2012)

2014-present Independent Safety Monitor, “The Use of a Transdermal Patch for Drug Delivery- Nicotine.” Investigators: Samer El-Kamary and Wilbur Chen (review safety issues throughout study)

2015-present Independent Safety Monitor, “The Use of a Transdermal Patch for Fentanyl Drug Delivery.” Investigators: Samer El-Kamary and Wilbur Chen (review safety issues throughout study)

National Service: 1997, 1998 Judge, Uniformed Services Pediatric Seminar (USPS), Scientific Awards

Competition (judged annual research submissions for USPS national meeting) 2004 Primary Reviewer, US Agency for International Development Grant Applications

in Health, sponsored by the National Academy of Sciences (October 26, 2004) (reviewed grant applications for clinical research abroad funded by USAID)

2004 Independent Safety Monitor, “Use of in vivo Expression Technology to Identify Virulence Factors and Protective Antigens of Vibrio cholerae O1,” performed at University of Maryland School of Medicine

2005 Independent Safety Monitor, “Comparisons of the Reactogenicity and Immunogenicity in Ambulatory Elderly Subjects of Standard Dose Fluzone and High Dose of a Trivalent, Inactivated Influenza Virus Vaccine,” performed at University of Maryland School of Medicine and other sites

2005 Member, Safety Monitoring Committee “Phase I Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium falciparum and Plasmodium vivax Malaria, performed at Johns Hopkins University School of Public Health

2005 Member, Safety Evaluation Committee “A Phase I, Single-Center, Double-Blinded, Placebo-Controlled, Randomized, Dose-Escalation Study to Compare the Safety, Tolerability, and Immunogenicity of Three Intramuscular Administrations of Na-ASP-2 Hookworm Vaccine in Healthy Adults without Evidence of Hookworm Infection,” performed at the George Washington University School of Medicine, sponsored by the Sabin Foundation

2005 Chair, Safety Monitoring Committee, “A Phase 1b, multi-centre, parallel group, single blind study to evaluate the safety, tolerability and immunogenicity of a recombinant plague vaccine (rF1 and rV antigens) in healthy subjects” performed in the UK by DSTL Porton Down with sponsorship from Avecia and support from DMID/NIAID/NIH

2006 Reviewer, Pediatric Infectious Disease Society 2006 MedImmune Career Development Awards (reviewed multiple grant applications for PIDS)

2006 Chair, Safety Monitoring Committee, “Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Vaccine, CVD


11

1208S(pCFA/1-LThA2B)” performed in Baltimore by the CVD with sponsorship from DMID/NIAID/NIH

2006 Chair, Safety Monitoring Committee, and Independent Safety Monitor “Phase 1, Dose-Escalating Trial in Healthy North American Adults of Sindbis-Based, Measles DNA Vaccines pMSIN-H and pMSINH-FdU Administered by a Needle-Free Injection Device” performed in Baltimore at the CVD under funding from The Bill and Melinda Gates Foundation

2006 Member, Safety Monitoring Committee, “A Phase II Dose-Finding Pilot Study for Development of an Anti-Influenza A (H5N1) Intravenous Hyper-Immune Globulin” sponsored by NIAID/NIH

2006 Reviewer, Career Development Grant Awards, Mid-Atlantic Regional Center for Excellence in Biodefense and Emerging Infectious Pathogens. (review all grant applications)

2006 Independent Safety Monitor, “Prevnar CVD 4000: Study of Immunosenescence” Principal Investigators: Drs. Alan Cross and Jan Cerny, University of Maryland Center for Vaccine Development

2007 Moderator, Society for Healthcare Epidemiology of America 17th Annual Scientific Meeting, Plenary session on “Cutting Edge Issues in Vaccines for Healthcare Workers.” Baltimore, MD (April 12-16, 2007)

2007 Member, Safety Monitoring Committee, “Double-blind, Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of Na-asp-2 Hookworm Vaccine in Previously Infected Brazilian Adults” performed in Brazil; PI David Diemert; sponsored by the Sabin Vaccine Institute

2012-2014 Member, Data Safety Monitoring Committee, “Discontinuation of trimethoprim-sulfamethoxazole prophylaxis in adults on antiretroviral therapy in Kenya: a randomized trial.” PI: Christina Polyak at University of Washington

2015 Member, Safety Monitoring Committee, “A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of BCX4430 when Administered Intramuscularly in Healthy Adults.” DMID 14-0030. PI: Collier.

International Service: 2001 Temporary Advisor to the World Health Organization Global Task Force on

Cholera for the design and implementation of an urgent nationwide vaccination campaign against epidemic cholera in the Republic of the Marshall Islands (traveled to the Marshalls together with 2 other experts, developed a plan for control of cholera on these islands, following an outbreak; primary role was providing technical expertise on an oral cholera vaccine and working with the Ministry of Health to implement a vaccination campaign)

2001 Consultant to the World Health Organization, Joint Tropical Disease Research and Infectious Disease Research Institute Leishmania vaccine clinical trial development; Geneva December 6-7, 2001 (provided technical expertise on


12

clinical trial performance and leishmaniasis) 2003 Temporary Advisor to the World Health Organization for use of intranasal

devices in delivery of measles vaccines; Geneva, April 17, 2003 (provided technical expertise on intranasal delivery and performance of vaccine trials in the U.S.)

2003 Consultant to GlaxoSmithKline on ethical issues in the use of antimalarial drugs in the developing world; London, UK, August 28-29, 2003 (together with several ethicists from various parts of the world, provided opinion on the testing and eventual deployment of new anti-malarial compounds)

2004 Chairman, Committee on Standardization of Streptococcus pyogenes Epidemiological Studies—Pharyngitis, Impetigo, and Invasive Disease, sponsored by National Institute of Allergy and Infectious Diseases (NIH) and the World Health Organization (wrote harmonized methods for surveillance of group A streptococcal disease, primarily for developing country investigators, adopted by WHO as standard for future studies around the globe)

2005 Temporary Advisor to the World Health Organization for use of intranasal devices and aerosol devices in the delivery of measles vaccines; Geneva, Switzerland, November 7-8, 2005 (provided technical expertise on intranasal spray and aerosol delivery and reported results of my vaccine trial in Santiago, Chile)

2005 Temporary Advisor to the World Health Organization and Pan-American Health Organization on Vaccine Stabilization & Delivery of Dry Powder Vaccines; PAHO Headquarters, Washington, D.C., December 15-16, 2005. (provided technical expertise on clinical development plans for evaluating safety in human vaccine trials)

2006 Temporary Advisor to the World Health Organization on pandemic influenza vaccines; Geneva, February 15-16, 2006 (provided technical expertise on pediatric pandemic influenza vaccine trials in the U.S.)

2007-2009 Member, Brighton Collaboration on standardization of events following vaccinations, Committee on Diarrhea

2014 Advisor to Dr. Samba Sow, who leads the Ministry of Health of the Republic of Mali Task Force on Ebola and Viral Hemorrhagic Fevers- national plan, prevention, containment, isolation, diagnosis

2015 Independent Consultant to the Ministry of Health and Malaria Control Program in the Republic of Equatorial Guinea, the National Ethical Committee of Equatorial Guinea (CENGE), in the establishment of the first IRB and in review of the first clinical trial in the country, Malabo, EG. January 11-17, 2015.

2015 Consultant to WHO: Standardizing the care of children with Ebola in West Africa and future outbreaks. Geneva, Switzerland. March 25-26, 2015.

2015 Member, Safety Monitoring Committee, “Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and


13

Infants.” Manufacturer and Sponsor: Sanaria. Editorial Tasks: (each journal, 0-2 reviews per year) 2002 Reviewer, Vaccine 2002 Reviewer, American Journal of Epidemiology 2003 Reviewer, Annals of Internal Medicine 2003 Reviewer, Expert Opinion on Biological Therapy 2003 Reviewer, FEMS Immunology and Medical Microbiology 2005 Reviewer, Lancet 2005 Reviewer, American Journal of Preventive Medicine 2005 Reviewer, Expert Review of Vaccines 2005 Editorial Board, Academic Editor, PLoS Clinical Trials 2005 Reviewer, International Journal of Infectious Diseases 2005 Reviewer, Epidemiologic Reviews 2006 Reviewer, Nature Reviews Immunology 2006 Reviewer, Journal of Infectious Diseases 2013 Reviewer, Clinical and Vaccine Immunology

Teaching Service National Naval Medical Center, Walter Reed Army Medical Center, and USUHS: 1993-1994 Morning Report, Lectures given as Chief Resident, National Naval Medical

Center (daily lectures or instructive cases presented every morning for 3 months, attendance 20 to 30 per session)

1996-1998 Resident Core Conference Lectures, 12 per year, each 1 hour, typical attendance of 20, National Naval Medical Center

1996-1998 Medical Student Introduction to Clinical Pediatrics, 1 class per year, National Naval Medical Center

1996-1998 Outpatient Pediatric Sub-internship Preceptor and Coordinator, 6 per year, National Naval Medical Center (involved daily close mentoring and teaching of fourth year medical students in my clinic, as well as supervising all sub-interns in the entire clinic)

1996-1998 Clinic Nurse and Corpsman Lecture Series, 3 lectures per year covering various outpatient pediatric topics, typical attendance 10 to 15, National Naval Medical Center (series initiated by me to provide core pediatric lectures to the non-physician providers in the clinic)

Guam Naval Hospital 1994-1996 Originator and Primary Educator, Island-wide Asthma Education Program for

Families on Guam, lectures 4 times per year (evening sessions with 10 to 30 attendees; presented a community-oriented talk on childhood asthma, organized


14

advertising for the sessions, and assisted others in their presentations, including nurses and respiratory therapists)

University of Maryland School of Medicine and University of Maryland Hospital for Children Clinical 1998-2007 Resident Core Conference Lectures, 5 per year, each one hour in length, typical

attendance 15 to 30, University of Maryland Hospital for Children (didactic sessions on a variety of Pediatric Infectious Disease topics followed by board review questions on the topic)

1998-2007 Pediatric Resident Infectious Disease Elective, 12 per year, involving patient rounds, case conferences, and mini-lectures on various Pediatric Infectious Disease topics, University of Maryland Hospital for Children

1998-2007 Medical Student Pediatric Infectious Disease Elective, 6 per year, involving patient rounds, case conferences, and mini-lectures on various Pediatric Infectious Disease topics, University of Maryland Hospital for Children

1999 Lecturer, Annual Maryland Cares Pediatric Conference, approximately 200 attendees, University of Maryland School of Medicine

2000-2007 Instructor, Pediatric Physical Diagnosis Course: instructing sophomore medical students on physical diagnosis of children, typically 5 to 10 students, involves teaching exam techniques on newborns, infants, or older children admitted to the hospital

2001-2007 Lecturer, Infectious Disease Lecture Series for Board Review. Topics: Febrile Exanthems of Childhood, Pediatric Vaccines, others; typical attendance of 10; University of Maryland School of Medicine, Adult Infectious Disease Fellowship Program

2001-2007 Teaching Attending, General Pediatric Ward, 6 weeks per year, University of Maryland Medical Center, involved tutorials for all medical students (typically 12), reading and critiquing written and oral histories and physical exams (4 per student per rotation), an observed history and physical with each student and junior resident, and participation in various group teaching sessions, such as morning report, throughout the 6-week session

2012-present Resident Core Conference Lectures, 2-5 per year, each one hour in length, typical attendance 15 to 30, University of Maryland Hospital for Children (didactic sessions on a variety of Pediatric Infectious Disease topics followed by board review questions on the topic- herpes simplex infections in children, enteroviruses, etc.)

2012-present Pediatric Infectious Diseases Journal Club, faculty advisor/organizer (assist the fellow with his/her choice, review and assist with presentation of a recent article on a topic in Pediatric Infectious Diseases; articles are discussed monthly with a group of ~8)

Student/Basic/Lectures


15

1999-2007 Lecturer, Medical School second year class course “Host Defenses and Infectious Diseases,” small group sessions of approximately 15 students discussing 3 infectious disease cases (yearly) and lecture to the entire class of approximately 150 students (Viral Syndromes of Childhood one year; Viral Respiratory Pathogens, Polio and Non-polio Enteroviruses yearly, beginning in 2005 and 2006 respectively)

2002-2007 Lecturer, Vaccinology Course, University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, 2 classes: Phase 1-4 Clinical Trials and Pediatric Vaccine Trials (~10 students plus visitors each session)

2003-2007 Lecturer, Interdisciplinary Course on Homeland Security at the University of Maryland School of Law attended by both law and medical students (total enrollment 12 to 50) “Biodefense and the Center for Vaccine Development,” course director Michael Greenberger, J.D., taught each year

2005 Lecturer, Introduction to Clinical Medicine. Presented overview of vaccine research at the Center for Vaccine Development to the incoming medical school first year class

2005-2007 Lecturer, Graduate Studies in Biodefense, Department of Pathology, University of Maryland School of Medicine. Yearly graduate course involving seminar style teaching with 1 to 6 students. Topic: Biodefense Vaccines

2005-2007 Lecturer, University of Maryland School of Medicine, Clinical Trials, Course Directors Roberta Sherer and Patricia Langenberg. Lecture Topic: Vaccine Trials

2009-2012 Course Director- Practices and Principles of Clinical Research, taught for all research scientists in two rural Ugandan research centers working on HIV and other endemic diseases

2010 Guest Lecturer- Use of CD4 and VL tests in the follow-up of Ugandan patients. Diploma in Tropical Medicine and Hygiene (DTMH) co-sponsored by London School of Tropical Medicine and Hygiene, Johns Hopkins University, and Makerere University College of the Health Sciences (~20 students from numerous countries)

2011 Guest Lecturer- Nodding Syndrome. Diploma in Tropical Medicine and Hygiene (DTMH) co-sponsored by London School of Hygiene and Tropical Medicine, Johns Hopkins University, and Makerere University College of the Health Sciences (~30 students from numerous countries)

2013-present Lecturer- Vaccinology Course, University of Maryland School of Medicine, Department of Epidemiology and Preventive Medicine, Assessment Methods for Vaccine Coverage and Ebola Vaccines (~10 students plus visitors)

2013 Lecturer- Graduate Program in the Life Sciences (GPILS): Regulatory Review of Clinical Translational Research by the Institutional Review Board (6 graduate students)

2013-present Lecturer- Small Group Sessions, School of Medicine, Epidemiology case discussions- outbreaks and screening tests (sensitivity, specificity, predictive


16

values), case control studies and cohorts, causation; second year medical students (4 to 6 sessions per year, ~20 students per session)

2013-present Lecturer- Small Group Sessions on Responsible Conduct of Research, first year medical students (1 session per year, ~20 students per session)

2014 Lecturer- Small Group Sessions, School of Medicine, How to Critically Analyze the Medical Literature, a randomized control trial (DCCT) and a screening program (ADA screening recommendations for type II diabetes), second year medical students (1 session per year, ~20 students per session)

2014 Lecturer- Responsible Conduct in Research, an Interdisciplinary Course. International Research Ethics. Taught to graduate students on the University of Maryland Baltimore campus (1 session per year, ~3 students per session)

2015 Lecturer- Principles of Global Health, University of Maryland School of Nursing. Guest Lecturer on “Ebola- the Epidemic and Response, including Vaccine Development”. (11 students) March 4, 2015.

Mentoring 2003-2005 Mentor, Pediatric Infectious Disease Fellow (Jakub Simon, M.D., M.S.) career

development advice in second and third year of fellowship, close supervision in performance of influenza and measles vaccine trials, and assistance in preparing NIH mentored career development award. Dr. Simon successfully received K23 award under my mentorship and became faculty in our department (5 contact hours per week)

2004-2007 Mentor, First to Fourth Year Medical Students (Samriti Dogra, Kathleen Sterling) interested in career in Pediatrics, the University of Maryland School of Medicine Mentoring Program (involved intermittent meetings and other communications to assist mentee throughout medical school; 5 contact hours per year)

2005-2007 Mentor, Pediatric Infectious Disease Fellow (Melissa Rosenberg, M.D.) career development advice in second and third year of fellowship and supervising work on the epidemiology of group A streptococcal diseases (pharyngitis and rheumatic heart disease) in school-age children in Bamako, Mali as part of streptococcal vaccine development plan; also mentored Dr. Rosenberg on influenza vaccine safety project funded by the CDC and as a sub-investigator on numerous clinical vaccine trials (3 contact hours per week)

2013-present Mentor, Pediatric Interns. Five Pediatric faculty members each mentor 3 interns per year; includes academic, professional, and personal mentoring; individualized learning plans, reviews of each monthly clinical rotation, and working with other mentors and the academic division on educational research (2 contact hours per month)

2015-2016 Mentor, High School Intern, The Gifted and Talented HS Mentor/Intern Program, Howard High School. Valerie Greisman, Senior, mentored in various aspects of clinical care, research, ethics and performing a cross-sectional survey of vaccine study participants and their knowledge, attitudes, and opinions on motivations for


17

participation as a healthy subject (4 hours per week). Grant and Contract Support Grants: Completed Grants 1999-2001 James D. Campbell (Vaccinology Fellow, 100%) PI MM Levine “Institutional National Research Service Award (T32-AI-07524): Vaccinology” Training Grant National Institutes of Health, peer reviewed Role: Fellowship research: antibody avidity, trials, epidemiology 2000-2005 James D. Campbell (Investigator) PI MM Levine “Development of a “stealth” mucosal measles vaccine that can immunize young

infants (2-6 months of age) in developing countries, despite the presence of maternal antibodies.”

Sponsor: Bill and Melinda Gates Foundation (peer reviewed) Total annual costs: $4,095,000

Role: Investigator (Principal Investigator of a retrospective study and then the largest prospective epidemiology study under this funding, involving clinical and microbiologic surveillance of all febrile inpatient children in Bamako, Mali [approximately 7000 children over the first 3 years], supervision of a team of Malian researchers, and the establishment and upkeep of a modern microbiology laboratory in the pediatric hospital in Bamako. These efforts led to national introduction of Hib conjugate vaccine by the Ministry of Health. I also have assisted in the performance of a clinical vaccine trial and other projects in Mali.)

2001-2003 James D. Campbell (PI, 20%) “Group A Streptococcal Disease: Burden of Disease in Bamako, Mali and a New

Correlate of Protective Immunity” (02-1-31022) Sponsor: University of Maryland School of Medicine Intramural Grant (peer

reviewed, internally) Total Direct Costs: $15,000 Role: surveillance, over two 3-month periods in Bamako, Mali, of group A

streptococcal pharyngitis, impetigo, and colonization; molecularly type isolates to determine distribution and to provide preliminary data for larger group A streptococcal surveillance (see below); supervised Malian clinical physician researchers, microbiology technicians, and an American medical student

2003-08 James D. Campbell (Investigator, 5%) PI K Kotloff “Improving the Expanded Program on Immunization in Mali”


18

Sponsor: Merck Vaccine Network-Africa (peer reviewed) Annual direct costs: $195,674 Role: improve vaccine services in Mali through education of immunization providers; assisted with the original plan, but only played a minor role in its implementation

Contracts: Active Contracts 2012-present James D. Campbell (Investigator, 5%) PI MM Levine “Assesment of the Effectiveness of Infant Immunization Services in Ethiopia” Sponsor: John Snow International Funder: The Bill and Melinda Gates Foundation (OPP1017350) Total direct costs: $940,520 Role: inform an Ethiopian Federal Ministry of Health (FMPH) evidence-based

decision on nationwide universal child immunization; supervised the serosurvey while living in Ethoipia for 1 month in 2013 and another in 2015

2013-present James D. Campbell (Co-Principal Investigator, 20%) PI K Kotloff “Vaccine and Treatment Evaluation Units (VTEU-Clinical testing of vaccines and

related products in human subjects.) Award HHSN272201300022I (9/16/2013- 9/15/2023). Sponsor: National Institutes of Health, NIAID. (peer reviewed)

Annual direct costs: IDIQ- minimum $10,000; max $95,170,200. Role: major role as an investigator and manager 2014-present James D. Campbell (Investigator, 10%) PI: K Lyke “A Phase I, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety,

Tolerability and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccines (cAd3-EBO), VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ), in Healthy Adults.” VRC 207

(NIH 14-I-0183) Sponsor: Vaccine Research Center/NIH (with contract via EMMES) Total direct costs: $246,366 Role: protocol development, screen, enroll, vaccinate, follow-up participants 2014-present James D. Campbell (Investigator, 4%) PI: MM Levine “A Phase Ib, Dose-Escalating, Safety and Immunogenicity trial of the novel

monovalent Ebola Zaire candidate vaccine, cAd3-EBO Z in Malian adults aged 18-50 years (EBL02)”

Sponsor: University of Oxford, UK Funding: Wellcome Trust (Strategic Translation Award) Total direct costs: $654,200


19

Role: protocol development, regulatory assistance; oversee screening, enrollment, vaccination, follow-up of Malian participants

2015-present James D. Campbell (PI, 5%) “A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to

Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women (V98_12, BB IND 15652)”

Sponsor: Novartis Vaccines and Diagnostics Total estimated direct costs: $110,774 Role: As PI, I will oversee the work performed at the Family and Community

Medicine Clinic at the University of Maryland site as well as at the adjacent University of Maryland Medical Center, where enrolled infants will be born. All vaccine trial events will occur at our Baltimore campus at these locations.

Completed Contracts 2005-2007 James D. Campbell (PI, 5%)

“A phase IIIb, open, randomized, controlled, multicenter study of the immunogenicity and safety of GlaxoSmithKline Biologicals’ inactivated hepatitis A vaccine (Havrix) [720 El.U/0.5 mL dose] administered on a 0, 6-month schedule concomitantly with Merck and Company, Inc. measles-mumps-rubella vaccine (M-M-R II) and Merck Company, Inc. varicella vaccine (VARIVAX) to healthy children 15 months of age” Sponsor: Glaxo Smith Kline Biologicals Total direct costs: $39,900

2005-2007 James D. Campbell (PI, 5%)

“A Phase I/II, 2 Stage, Randomized, Double-Blind Trial of the Safety, Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine (Serotypes 1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F,23F) in Healthy Infants. (Wyeth: 6096A1) Sponsor: Wyeth Vaccines Total direct costs: $87,569


“Safety and Immunogenicity of a Tetravalent (A, C, Y, and W-135) Meningococcal Diphtheria Toxoid Conjugate Vaccine (TetraMenD) In Toddlers 9 to 18 Months of Age” (sanofi pasteur: MTA26) Sponsor: sanofi pasteur Total direct costs: $32,964



20

“Immunogenicity and Safety of Meningococcal (Groups A,C,Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra™) in Adolescents in the US when Administered Concomitantly with Tetanus and Diptheria Toxoids Adsorbed Combined with Component Pertussis (TdcP) Vaccine” (sanofi pasteur: MTA21) Sponsor: sanofi pasteur Total direct costs: $40,437

2005-2007 James D. Campbell (PI, 5%) “A Phase III, Observer-Blind, Randomized Study to Evaluate the Immunogenicity and Safety of Fluarix (GlaxoSmithKline Biologicals) Compared With Fluzone® (Sanofi Aventis) Administered Intramuscularly in Adults 18 Years and Older in the U.S.” (FluarixUS-003) Sponsor: sanofi pasteur Total direct costs: $177,000


“Expanded phase II and IV vaccine trials in humans” Sponsor: National Institutes of Health (peer reviewed)

Total direct costs: $100,000 to $3,000,000 per year (indefinite delivery / indefinite quantity contract)

Role: I became PI on this contract in 2005. 2002-07 James D. Campbell (Investigator, 15%) PI MM Levine “Evaluation of control measures against infectious diseases other than AIDS.

(Clinical testing of vaccines and related products in healthy human subjects.)” National Institutes of Health, NIAID (peer reviewed) Award NO1-AI-25461

(6/1/02 - 5/31/07). Annual direct costs: $3,043,414 Role: large role as an investigator: performed the following clinical trials as

Principal Investigator under this award: Phase I recombinant anthrax vaccine trial (80 volunteers), Phase III inactivated influenza vaccine trial (264 volunteers), Phase I/II avian influenza vaccine trial (154 volunteers), Phase I/II avian influenza vaccine trial among production line workers (84 volunteers), Phase II avian influenza vaccine trial among children 2-9 years old (40 volunteers, I was also the national coordinating PI for all pediatric sites), Phase II adjuvanted avian flu vaccine (160 volunteers), Phase I whole virus cell-cultured avian flu vaccine among adults (100 volunteers), a Modified Vaccinia Ankara (smallpox vaccine) trial; also, a co-investigator on other trials under this contract, including a Phase I group A streptococcal vaccine trial, a Phase I malaria vaccine trial, an inpatient oral attenuated Shigella vaccine trial, and an adjuvanted inactivated avian flu vaccine for the elderly. (Of the 12 studies performed under this contract in the first 4 years, I was PI on 6, a co-investigator on 4, and the Independent Safety


21

Monitor on 1.) 2002-2007 James D. Campbell (PI, 5%)

“Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (TdcP) Vaccine Compared to Tetanus and Diphtheria Toxoids Adsorbed (Td) in Adolescents and Adults 11-64 Years of Age. (Td506)” Sponsor: sanofi pasteur Total Direct Costs: $21,242

2006-2007 James D. Campbell (PI, 5%) “Persistence of Bactericidal Antibodies in Children Aged 7 to 15 Years who Received a Single Dose of Menactra or Menomune-A/C/Y/W-135 Five Years Earlier (sanofi pasteur MTA23)” Sponsor: sanofi pasteur Total direct costs: $24,400

2006-2007 James D. Campbell (PI, 5%) “Comparative Immunogenicity of Different Multivalent Component Pertussis Vaccine Formulations Based on 5-Component Acellular Pertussis Vaccine in Infants and Toddlers (sanofi pasteur M5A10)” Sponsor: sanofi pasteur Total direct costs: $135,400

2006-2007 James D. Campbell (PI, 5%) “A Phase IV, Randomized, Partially Blinded Multicenter Study to Evaluate the Safety and Immunogenicity of a Booster Vaccination with GlaxoSmithKline's Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine, Adsorbed [Tdap Boostrix] Co-Administered Intramuscularly with Aventis-Pasteur's Meningococcal (Serogroups A, C, Y And W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine [Menactra] as Compared to the Administration of Either Vaccine Alone in Healthy Adolescents 11-18 Years of Age (GSK Tdap 0.3-006)” Sponsor: GlaxoSmithKline Biologicals Total direct costs: $69,125

2006-2007 James D. Campbell (PI, 5%) “Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: Adacel and Boostrix. (sanofi pasteur Td516)” Sponsor: sanofi pasteur Total direct costs: $168,000


22


“Safety and Immunogenicity of a Meningococcal (Groups A, C, Y, And W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Subjects Over 55 Years of Age (sanofi pasteur MTA29)” Sponsor: sanofi pasteur Direct Costs: $45,000

2006-2007 James D. Campbell (PI, 5%) “A Phase 3, Observer-blind, Randomized, Parallel, Multi-Center, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine When Administered with Routine Infant Vaccinations to Healthy Infants at 2, 4 or 2, 4, 6 Months of Age Followed by a Booster at 12 or 16 Months of Age and Immunogenicity of a Single-Dose of Licensed Meningococcal Polysaccharide Vaccine, Menomune®, when Administered to Children 3 – 5 Years of Age (Open–Label)” (IND 11278) Sponsor: Novartis Total direct costs: $180,000

2006-2007 James D. Campbell (PI, 5%) “A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to Healthy Adolescents 11-18 Years of Age and to Compare the Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine with that of Licensed Meningococcal ACWY Conjugate Vaccine (Menactra™) when One Dose is Administered to Healthy Subjects 11-55 Years of Age (IND 11278)” Sponsor: Novartis Total direct costs: $90,000

2007 James D. Campbell (PI, 5%) “Safety and Immunogenicity of Adacel (Tdap Vaccine) Compared to Daptacel (DTaP Vaccine) as Fifth Dose Booster in Children 4 to 6 Years of Age. (sanofi pasteur Td517)” Sponsor: sanofi pasteur Total direct costs: not determined at the time of my departure for Uganda

2012-2014 James D. Campbell (PI, 25%) “Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure

Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples” (IND 75,365)

Sponsor: University of Washington International Clinical Research Center


23

Funder: The Bill and Melinda Gates Foundation Annual direct costs: $78,640 Role: While working for the CDC in Uganda from 2007 to 2012, I was PI for 2 of

9 sites in this clinical trial of HIV pre-exposure prophylaxis for discordant couples in East Africa. From 2012-2014, I remained PI but as a subcontractor at the University of Maryland School of Medicine.

Cooperative Agreements: Active Cooperative Agreements 2014-2019 James D. Campbell (PI Clinical Core, 15%) PIs: P Bavoil, J Ravel “Ecopathogenomics of sexually transmitted infections (EPSTI)” U19 AI084044-

06 (9/1/2014-8/31/2019) Sponsor: National Institutes of Health, NIAID (peer reviewed) Role: lead all clinical research activities, supervise clinical research team Total direct costs: $7,899,708 over 5 years. Completed Cooperative Agreements 2002-2005 James D. Campbell (PI, 10%) “Phase I trial of intranasal measles vaccine” Award 02167 (9/30/02 - 9/29/05)

Sponsor: Centers for Disease Control and Prevention (peer reviewed) Total direct costs: $137,213 (plus supplemental funds for animal pre-clinical work awarded 9/15/03: additional costs $211,000)

2003-2008 James D. Campbell (Investigator, 10%) PI MM Levine “Regional Center for Excellence (RCE) in Biodefense and Emerging Infectious Pathogens, Mid-Atlantic Region: NIH Cooperative Agreement No. U54 AI056578.” (9/4/03 - 2/29/08) Sponsor: National Institutes of Health, NIAID (peer reviewed) Total direct costs: $36,986,023 Role: PI for vaccine trials in the clinical core (RCE was a large consortium of institutions performing biodefense-related research. I was a clinical investigator in the Public Health Response group and responsible for vaccine trials.)

2003-2007 James D. Campbell (Investigator, 20%) PI MM Levine “Regional Center for Excellence in Biodefense and Emerging Infectious Pathogens, Mid-Atlantic Region NIH Cooperative Agreement No. U54 AI056578. (9/4/03 - 2/29/08)” Sponsor: National Institutes of Health, NIAID (peer reviewed) Career Development Award Annual direct costs: $86,000


24

Role: MM Levine was PI of the entire MARCE; I was PI of the career development award, a K23-equivalent.

2004-2007 James D. Campbell (Investigator, 10%) PI: James Dale (Veterans Affairs Medical Center and University of Tennessee, Memphis, TN)

“The Development of a Vaccine against Streptococcus pyogenes (Group A Streptococcus) (U01)”

Sponsor: National Institutes of Health (peer reviewed) Annual direct costs: $500,000 overall; $75,000 for my projects Role: Investigator of the molecular epidemiology of group A streptococcus and

rheumatic heart disease in 10,000 African children Publications Peer-reviewed Journal Articles: 1. Campbell, JD and Nataro, JN. Pleural Empyema. Pediatr Infect Dis J 1999; 18(8): 675-6. 2. Campbell, JD and Levine, MM. Vaccines Against Enteric Bacterial Pathogens. Asian Journal

of Paediatric Practice 2001; 5(2):19-37. 3. Treanor J, Keitel W, Belshe R, Campbell J, Schiff G, Zangwill K, Wolff M, Klimov A,

Levandowski R, Lambert L. Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adults. Vaccine 2002 Jan 15;20(7-8):1099-1105.

4. Kotloff KL, Taylor DN, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, Levine MM, Hale TL. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infection and Immunity 2002 Apr;70(4):2016-21.

5. Surinayam K, Campbell JD, Ashkenazi A. Nontuberculous mycobacterial infections in pediatric acute leukemia. J Pediatr Hematol Oncol 2002 Oct;27(7):558-60.

6. Lichenstein R, Suggs AH, Campbell JD. Pediatric Pneumonia. Emergency Clinics of North America, May 2003; 21(2):437-52.

7. Levine MM, Campbell JD, Kotloff KL. Overview of vaccines and immunisation. British Medical Bulletin 2002;62:1-13.

8. Kamal-Bahl S, Doshi J, Campbell JD. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: A systematic review. Arch Pediatr Adolesc Med 2002 Oct;156(10):1034-41.

9. Campbell JD, Lagos R, Levine MM, Losonsky GL. Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants. Pediatr Infect Dis J 2002. Sep; 21(9): 822-826.

10. Campbell JD, Edelman R, King JC, Papa T, Ryall R, Rennels MB. Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults. J Infect Dis 2002;186:1848-51.


25

11. Shamoo AE, Campbell JD. The use of experimental drugs during national crisis. Accountability in Research 2003;10:69-84.

12. Campbell JD, Sow SO, Levine MM, Kotloff KL. The causes of hospital admission and death among children in Bamako, Mali. J Trop Pediatrics 2004; 50 (3): 158-163.

13. Campbell JD, Kotloff KL, Sow SO, Tapia M, Keita MM, Keita T, Diallo S, Hormazabal JC, Murray P, Levine MM. Invasive Pneumococcal Infections Among Hospitalized Children in Bamako, Mali. Pediatr Infect Dis J 2004 July; 23 (7): 642-9.

14. Kotloff KL, Corretti M, Palmer K, Campbell JD, Reddish MA, Hu MC, Wasserman SS, Dale JB. Safety and immunogenicity of a recombinant multivalent group A streptococcal vaccine in healthy adults. Phase I trial. JAMA 2004; 292:709-15.

15. Sow SO, Diallo S, Campbell JD, Tapia M, Keita T, Keita MM, Murray P, Kotloff KL, Levine

MM. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: Impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J 2005 June; 24 (6):1-5.

16. Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, Innis BL. Rapid licensure of a new, inactivated influenza vaccine in the United States. Human Vaccines November/December 2005; 1(6): 239-244.

17. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Evaluation of the safety and immunogenicity of an inactivated subvirion H5N1 influenzavirus vaccine in humans. New England Journal of Medicine March 30, 2006; 345(13): 1343-51.

18. Giudice EL and Campbell JD. Needle-free Vaccine Delivery, in Drugs and Macromolecules Delivery in Pediatrics: Challenges and Opportunities. Advanced Drug Delivery Reviews 58 (2006) 68-89.

19. Campbell JD. Vaccines to protect humans from pandemic avian influenza strains. Maryland Medical Journal 2006;7(1):15-18.

20. Harrington SM, Stock F, Kominski AL, Campbell JD, Hormazabal JC, Livio S, Rao L, Kotloff KL, Sow SO, and Murray PR. Genotypic Analysis of Invasive Streptococcus pneumoniae from Mali, Africa Using Semi-automated rep-PCR and Pulsed-Field Gel Electrophoresis. J Clin Micr March 2007 45(3):707-14.

21. Simon JK, Pasetti MF, Viret J-F, Mischler R, Munoz A, Lagos R, Levine MM, Campbell JD. A Clinical Study to Assess the Safety and Immunogenicity of Attenuated Measles Vaccine Administered Intranasally to Healthy Adults. Human Vaccines March/April 2007 3(2): 54-58.

22. Campbell JD, Donegan S, Long (Clement) K, Chrisley L, Wasserman SS, Kotloff KL. Safety, Reactogenicity, and Immunogenicity of a Recombinant Protective Antigen Anthrax Vaccine Given to Healthy Adults. Human Vaccines 2007 3(6).

23. Campbell JD. Pandemic flu vaccine: are we doing enough? Clinical Pharmacology & Therapeutics 2007 Dec; 82(6):633-5.

24. Karakousis PC, Sifakis FG, Montes de Oca R, Amorosa VC, Page KR, Manabe YC, Campbell JD. U.S. medical resident familiarity with national tuberculosis guidelines. BMC Infectious Diseases 2007; 7:89.


26

25. Manabe YC, Campbell JD, Sydnor E, Moore RD. Immune reconstitution inflammatory syndrome: risk factors and treatment implications. JAIDS 1 Dec 2007; 46(4):456-62.

26. Zangwill KM, Treanor JJ, Campbell JD, Noah DL, Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008 Feb 15; 197(4):580-3.

27. Keitel W, Campbell JD, Treanor JJ, Walter E, Patel S, He F, Noah D, Hill H. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given without or with aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infectious Dis 2008 Nov 1; 198(9):1309-16.

28. Page KR, Manabe YC, Adelakun A, Federline L, Cronin W, Campbell JD, and Dorman SE. Timing of therapy for latent tuberculosis infection among immigrants presenting to a U.S. public health clinic: a retrospective study. BMC Public Health. 2008 May 12;8:158

29. Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine 2008 Jul 29;26(32):4057-61.

30. Forna F, Moore D, Mermin J, Brooks JT, Were W, Buchacz K, Campbell JD, Downing R, Borkowf CB, Weidle PJ. Hematologic changes associated with zidovudine following single-drug substitution from stavudine in a home-based AIDS care program in rural Uganda. J Int Assoc Physicians AIDS Care (Chic Ill). 2009 Mar-Apr;8(2):128-38.

31. Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009 July 9; 27 (32): 4278-83.

32. Keitel WA, Dekker CL, Mink C, Campbell JD, Edwards KM, Patel SM, Ho DY, Talbot HK, Guo K, Noah DL, Hill H. Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults. Vaccine 2009 Nov 5;27(47):6642-8. Epub 2009 Mar 25

33. Bryant KA, Block SL, Baker SA, Gruber WC, Scott DA, for the PCV13 Infant Study Group. Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine. Pediatrics 125(5). May 1, 2010, pp. 866-875 (doi: 10.1542/peds.2009-1405).

34. Campbell JD, Chambers CV, Brady RC, Caldwell MC, Bennett NL, Fourneau MA, Jain VK, Innis BL. Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: A randomized study in US adults. Human Vaccines January 2011; 7(1): 81-88.

35. Gidudu J, Sack DA, Pina M, Hudson MJ, Kohl KS, Bishop P, Chatterjee A, Chiappini E, Compingbutra A, da Costa C, Fernandopulle R, Fischer TK, Haber P, Masana W, de Menezes MR, Kang G, Khuri-Bulos N, Killion LA, Nair C, Poerschke G, Rath B, Salazar-Lindo E, Setse R, Wenger P, Wong VC, Zaman K; Brighton Collaboration Diarrhea Working Group. Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine. 2011 Jan 29;29(5):1053-71. doi: 10.1016/j.vaccine.2010. 11.065. Epub 2010 Dec 3.


27

36. Simon JK, Ramirez K, Cuberos L, Campbell JD, Viret JF, Munoz A, Lagos R, Levine MM, Pasetti MF. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clinical and Vaccine Immunology, March 2011; 18 (3): 355-361.

37. Apondi R, Bunnell R, Ekwaru JP, Moore D, Bechange S, Khana K, King R, Campbell JD, Tappero J, Mermin J. Sexual behavior and HIV transmission risk of Ugandan adults taking antiretroviral therapy: 3 year follow-up. AIDS June 19, 2011; 25(10):1317-27.

38. Frenck R, Belsche R, Brady R , Winokur P, Campbell JD, Treanor J, Hay CM, Walter EB, Dekker C, Cate TR, Edwards K, Hill H; LeDuc T. Comparison of the Immunogenicity and Safety of a Split-virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered by Intradermal and Intramuscular Routes in Healthy Adults. Vaccine Aug 5, 2011; 29(34): 5666-74.

39. Simon JK, Carter M, Pasetti MF, Sztein MB, Kotloff KL, Weniger BG, Campbell JD, Levine MM. Safety, Tolerability, and Immunogenicity of Inactivated Trivalent Seasonal Influenza Vaccine Administered with a Needle-Free Disposable-Syringe Jet-Injector. Vaccine 2011 Nov 28;29(51):9544-50. (Epub 2011 Oct 8).

40. Mujugira A, Baeten JM, Donnell D, Ndase P, Mugo NR, Barnes L, Campbell JD, Wangisi J, Tappero JW, Bukusi E, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Panteleeff D, Krows M, Shah H, Revall J, Morrison S, Ondrejcek L, Ingram C, Coombs RW, Lingappa JR, Celum C, for the Partners PrEP Study Team. Characteristics of HIV-1 Serodiscordant Couples Enrolled in a Clinical Trial of Antiretroviral Pre-Exposure Prophylaxis for HIV-1 Prevention. PLoS ONE, Oct 2011; 6(10); e25828.

41. Mermin J, Ekwaru JP, Were W, Degerman R, Bunnell R, Kaharuza F, Downing R, Coutinho A, Solberg P, Alexander LN, Tappero J, Campbell JD, Moore DM. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. BMJ 2011;343:d6792 doi: 10.1136/bmj.d6792.

42. Asiimwe F, Moore D, Were W, Nakityo R, Campbell JD, Barasa A, Mermin J, Kaharuza F. Clinical Outcomes of HIV-infected patients with Kaposi’s sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda. HIV Med. 2011 Nov 24. doi: 10.1111/j.1468-1293.2011.00955.x

43. Moore DM, Yiannoutsos CT, Musick BS, Tappero J, Degerman R, Campbell JD, Were W, Kaharuza F, Alexander LN, Downing R, Mermin J. Determinants of early and late mortality among HIV-infected individuals receiving home-based antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):289-96.

44. Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, Odongo G, Wetaka M, Mermin J, Tappero JW. HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54(8):1204–11 (printed first online at doi: 10.1093/cid/cis013 on March 14, 2012).

45. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar


28

C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-Joloba E, Twesigye R, Ngure K, Apaka C, Tamooh H, Gabona F, Mujugira A, Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C, Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, and Celum C for the Partners PrEP Study Team. Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med 2012; 367:399-410.

46. Campbell JD, Herbst JH, Koppenhaver RT, Smith DK. Oral Antiretroviral Prophylaxis for Sexual and Injection Drug Use Acquisition of HIV: Review of Studies to Date. Amer J of Prev Med. Jan 2013; 44 (1), Supplement 2: A1-A4, S59-S172.

47. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, Njuguna S, Mugo N, Bukusi E, Manongi R, Baeten JM; Partners in Prevention HSVHIV Transmission Study and the Partners PrEP Study Teams. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):339-47. doi: 10.1097/QAI.0b013e31827e622d.

48. Ekwaru JP, Campbell J, Malamba S, Moore DM, Were W, Mermin J. The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy. J Int AIDS Soc. 2013 Apr 1;16:17355. doi: 10.7448/IAS.16.1.17355.

49. Mujugira A, Heffron R, Celum C, Mugo N, Nakku-Joloba E, Baeten JM; Partners PrEP Study Team. Fertility intentions and interest in early antiretroviral therapy among East African HIV-1-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2013 May 1;63(1):e33-5. doi: 10.1097/QAI.0b013e318288bb32.

50. Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, Mujugira A, Tappero J, Kahle EM, Thomas KK, Baeten JM, for the Partners PrEP Study Team. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS 2013 Aug 24, 27 (13): 2155-2160.

51. Haberer JE, Baeten JM, Campbell JD, Wangisi J, Katabira E, Ronald A, Tumwesigye E, Psaros C, Safren SA, Ware N, Thomas KK, Donnell D, Krows M, Kidoguchi L, Celum C, Bangsberg DR. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLOS Med. 2013;10(9):e1001511. PMCID: 3769210.

52. Mugwanya KK, Donnell D, Celum C, Thomas KK, Ndase P, Mugo N, Katabira E, Ngure K, Baeten JM; Partners PrEP Study Team. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis. 2013 Dec;13(12):1021-8. doi: 10.1016/S1473-3099(13)70226-3. Epub 2013 Oct 17.

53. Ndase P, Celum C, Campbell JD, Bukusi E, Kiarie J, Katabira E, Mugo N, Tumwesigye E, Wangisi J, Were E, Brantley J, Donnell D, Baeten for the Partners PrEP Study Team*. Successful discontinuation of the placebo arm and provision of an effective HIV prevention product after a positive interim efficacy result: the Partners PrEP Study experience. J Acquir Immune Defic Syndr. 2014;66(2):206-12.


29

54. Psaros C, Haberer JE, Katabira E, Ronald A, Tumwesigye E, Campbell JD, Wangisi J, Mugwanya K, Kintu A, Enyakoit M, Thomas K, Donnell D, Krows M, Kidoguchi L, Ware N, Baeten JM, Celum C, Bangsberg DR, Safren SA. An intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in HIV serodiscordant couples in Uganda. J Acquir Immune Defic Syndr. 2014 Aug 15;66(5):522-9. doi: 10.1097/QAI.0000000000000212. (published online 21 May 2014).

55. Lindan CP, Anglemeyer A, Hladik W, Barker J, Lubwama G, Rutherford G, Ssenkusus, Opio A, Campbell J. High-risk motorcycle taxi drivers in the HIV/AIDS era: a respondent driven sampling survey in Kampala, Uganda. International Journal of HIV/AIDS. 26 Jun 2014. doi:10.1177/0956462414538006.

56. Mugo NR, Hong T, Celum C, Donnell D, Bukusi EA, John-Stewart G, Wangisi J, Edwin Were E, Heffron R, Matthew LT, Morrison S, Ngure K, Baeten JM, MD, for the Partners PrEP Study Team. Pregnancy Incidence and Outcomes Among Women Receiving Preexposure Prophylaxis for HIV Prevention, A Randomized Clinical Trial. JAMA July 23/30 312 (4) 362-371.

57. Celum C, Morrow RA, Donnell D, Hong T, Hendrix CW, Thomas KK, Fife KH, Nakku-Joloba E, Mujugira A, Baeten JM; Partners PrEP Study Team. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Ann Intern Med. 2014 Jul 1;161(1):11-9. doi: 10.7326/M13-2471.

58. Manabe YC, Campbell JD, Ovuga E, Maling S, Bollinger RC, Sewankambo N. Optimisation of the Medical Education Partnership Initiative to address African health-care challenges. The Lancet Global Health: 2 (7) July, 2014 e392.

59. Murnane PM, Heffron R, Ronald A, Bukusi EA, Donnell D, Mugo NR, Were E, Mujugira A, Kiarie J, Celum C, Baeten JM; Partners PrEP Study Team. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS. 2014 Jul 31;28(12):1825-30. doi: 10.1097/QAD.0000000000000290

60. Mujugira A, Celum C, Thomas KK, Farquhar C, Mugo N, Katabira E, Bukusi EA, Tumwesigye E, Baeten JM; Partners PrEP Study Team. Delay of antiretroviral therapy initiation is common in East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):436-42. doi: 10.1097/QAI.0000000000000192.

61. Matthews LT, Heffron R, Mugo NR, Cohen CR, Hendrix CW, Celum C, Bangsberg DR, Baeten JM; Partners PrEP Study Team. High Medication Adherence During Periconception Periods Among HIV-1-Uninfected Women Participating in a Clinical Trial of Antiretroviral Pre-exposure Prophylaxis. J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):91-7. doi: 10.1097/QAI.0000000000000246.

62. Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, for the Partners PrEP Study Team. Single-Agent Tenofovir versus Combination Emtricitabine/Tenofovir for Pre-Exposure Prophylaxis


30

against HIV-1 Acquisition: A Randomized Trial. Lancet Infectious Diseases. November, 2014; 14 (11): 1055-1064. doi:10.1016/S1473-3099(14)70937-5 (published online: 07 October 2014).

63. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotlof KL, Berry AA, Graham I, Atmar, RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response, A Randomized Clinical Trial. JAMA July 21, 2015; 314(3):237-246 doi:10.1001/jama.2015. 7916.

64. Travassos MA, Beyene B, Adam Z, Campbell JD, Mulholland N, Diarra SS, Kassa T, Oot L, Sequeira J, Reymann M, Blackwelder WC, Pasetti MF, Sow SO, Steinglass R, Kebede A, Levine MM. Strategies for Coordination of a Serosurvey in Parallel with an Immunization Coverage Survey. Am J Trop Med Hyg. 2015 Aug 5; 93(2): 416–424. PMCID: PMC4530774 doi: 10.4269/ajtmh.15-0198.

65. Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, Sztein MB, Wahid R, Campbell JD, Kieny M-P, Moorthy V, Imoukhuede EB, Rampling T, Roman F, De Ryck I, Bellamy AR, Dally L, Mbaya OT, Ploquin A, Zhou Y, Stanley DA, Bailer R, Koup RA, Roederer M, Ledgerwood J, Hill AVS, Ballou WR, Sullivan N, Graham B, Levine MM. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo:a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases. Published online November 3, 2015 http://dx.doi.org/10.1016/S1473-3099(15)00362-X.

66. Morrison S, John-Stewart G, Egessa JJ, Mubezi S, Kusemererwa S, Bii DK, Bulya N, Mugume F, Campbell JD, Wangisi J, Bukusi EA, Celum C, Baeten JM; Partners PrEP Study Team. Rapid Antiretroviral Therapy Initiation for Women in an HIV-1 Prevention Clinical Trial Experiencing Primary HIV-1 Infection during Pregnancy or Breastfeeding. PLoS One. 2015 Oct 15;10(10):e0140773. doi: 10.1371/journal.pone.0140773. eCollection 2015. PMID: 26469986

67. Baeten J, Wangisi J, Campbell JD, et al. Rapid antiretroviral therapy initiation for women in an HIV-1 prevention clinical trial experiencing primary HIV-1 infection during pregnancy or breastfeeding. PLoS One. Accepted October 2015.

68. Okoboi S, Ekwaru JP, Campbell JD, Aggrey E, King R, Bakanda C, Muramuzi E, Kaharuza F, Malamba S, Moore DM. No differences in clinical outcomes with the addition of viral load testing to CD4 cell count monitoring among HIV infected participants receiving ART in rural Uganda: Long-term results from the Home Based AIDS Care Project. BMC Public Health 2016 (16) 101.

69. Travassos MA, Beyane B, Adam Z, Campbell JD, Mulholland N, Diarra SS, Kassa T, Oot L, Sequiera J, Reymann M, Blackwelder WC, Wu Y, Ruslanova I, Goswami J, Sow SO, Pasetti MF, Steinglass R, Kebede A, Levine MM. Immunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia. PLoS ONE 11(3):


31

e0149970.doi:10.1371/journal.pone.0149970. (published March 2, 2016)

Non Peer-reviewed Journal Articles: 1. Campbell JD and Rennels, MB. Pneumococcal Vaccines. Drugs of Today 1999; 35(6): 461-

72. 2. Campbell JD. Cat Scratch Disease. Tech Sample Microbiology 2001; MB-3:13-20. Book Chapters: 1. Campbell JD, Kotloff KL, and Levine MM. Specific and non-specific treatment of diarrhea.

In Infectious Diseases Third Edition; editors Gorbach SL, Bartlett JG, and Blacklow NR. Lippincott, Williams, and Wilkins, 2004.

2. Campbell JD and Kaper JB. Vaccines against Vibrio cholerae. In New Bacterial Vaccines; editors Ellis, RW and Brodeur, BR. Eurekah.com and Landis Bioscience, 2003.

3. Campbell JD and Levine MM. Cholera and Typhoid Vaccines for the International Traveler. In Travelers’ Vaccines; editors Jong, EC and Zuckerman JN. BC Decker, Inc., 2004.

4. Campbell JD and Burgess M. Heterogeneity of Pediatric Immunization Schedules in Industrialized Countries. In New Generation Vaccines Third Edition; editors Levine MM, Kaper, JB, Rappuoli R, Liu MA, and Good MF. Marcel Dekker, Inc., 2004

5. Levine MM and Campbell JD. Mucosal immunization and needle-free injection devices. In New Generation Vaccines Third Edition; editors Levine MM, Kaper, JB, Rappuoli R, Liu MA, and Good MF. Marcel Dekker, Inc., 2004.

6. Lodha R, Singhi SC, Campbell JD. Critical Viral Infections. In Rogers Textbook of Pediatric Intensive Care, Fourth Edition. 2007.

Abstracts: 1. Ralston M, Shope T, and Campbell JD. Use of Mupirocin or Cephalexin for Tropical

Ecthyma (“Guam Sores”). Western Pacific Infectious Disease Conference, Guam, 1994. 2. Collura-Burke C and Campbell JD. Steps Toward Safety: Use of Oral and Written Safety

Counseling with Parents of Newborns. Uniformed Services Pediatric Seminar, 1997. 3. Campbell JD, Lagos R, Levine MM, Losonsky GL. Full and fractionated doses of

Haemophilus influenzae type B (Hib) PRP-T vaccine induce similar IgG antibody avidity in Chilean children. Infectious Disease Society of America, New Orleans Sept 7-11, 2000.

4. Kotloff KL, Campbell JD, et al. Safety and immunogenicity of a hexavalent group A Streptococcal vaccine. Lancefield Streptococcal Conference, Goa, India October 2002.

5. Tapia, M, Campbell JD, Sow SO, Kotloff KL. Case-control study on risk factors for cholera in Djenne, Mali. Presented at Meeting of the American Society for Tropical Medicine and Hygiene. Denver, CO November 2002.

6. Shamoo AE, Campbell JD. The Use of Experimental Drugs During National Crisis.


32

Presented at Friends Research Ethics Conference On National Defense and Human Research Protections. Washington, D.C. October 21-23, 2002.

7. Campbell JD, Sow SO, Tapia M, Levine MM, Kotloff KL. Invasive Bacterial Infections in Children of Bamako, Mali. Presented at the Infectious Disease Society of America, San Diego, October 11, 2003.

8. Haidara FC, Tapia MD, Sow SO, Diallo S, Campbell JD, Doumbia MN, Keita MM, Onwuchekwa U, Keita MM, Sylla M, Levine MM, Kotloff KL. Mortality Among Children Admitted to a Pediatric Hospital in Bamako, Mali. Presented at the Annual Meeting of the American Society for Tropical Medicine and Health, Atlanta, 2006.

9. Keita MM, Sow SO, Campbell JD, Tamboura B, Tapia MD, Berthé A, Samaké M, Kotloff K. Group A Streptococcal Disease in Mali: Pilot Study. Presented at the Annual Meeting of the American Society for Tropical Medicine and Health, Atlanta, 2006.

10. Tapia MD, Campbell JD, Sow SO, Simon J, Roghmann M-C, Diallo S, Keita MM, Doumbia MN, Onwuchekwa U, Keita MM, Sylla M, Kotloff K, Levine MM. Bacterial Meningitis Among 0- to 15-year old Children Admitted to a Pediatric Referral Center in Bamako, Mali. Presented at the Annual Meeting of the American Society for Tropical Medicine and Health, Atlanta, 2006.

11. Sow SO, Tapia MD, Campbell JD, Diallo S, Keita MM, Doumbia MN, Onwuchekwa U, Keita MM, Sylla M, Levine MM, Kotloff K. Burden of Invasive Bacterial Infections among Children Admitted to a Pediatric Referral Center in Bamako, Mali – 2002 – 2006. Presented at the Annual Meeting of the American Society for Tropical Medicine and Health, Altlanta, 2006.

12. Simon JK, Pasetti MF, Viret JF, Muñoz A, Lagos R, Levine MM, Campbell JD. A Clinical Study to Assess the Safety and Immunogenicity of Attenuated Measles Vaccine Administered Intranasally to Healthy Adults. Presented at the Annual Meeting of the American Society for Tropical Medicine and Health, Atlanta, 2006.

13. Keitel W, Campbell J, Treanor J, Walter E, Patel S. A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or with Aluminum Hydroxide to Healthy Adults. Options for the Control of Influenza VI Conference. Toronto. June 17-23, 2007.

14. Campbell JD, et al A Phase III Study to Evaluate the Immunogenicity and Safety of Fluarix® Compared with Fluzone® in Adults in the U.S. Presented as an oral presentation at the Tenth Annual Conference on Vaccine Research sponsored by the National Foundation for Infectious Diseases. Baltimore, MD. April 30-May 2, 2007.

15. Bryant K, Block S, Scott D, for the 13vPnC Infant Study Group. Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine. Presented at the Pediatric Academic Society Meetings, Toronto, Canada; May 5-9, 2007 and at the European Society for Pediatric Infectious Diseases.

16. Zangwill K, Campbell JD, Treanor JJ, Noah D. Evaluation of a Third Dose of Subvirion H5N1 Influenza Vaccine (rgA/Vietnam/1203/04 x PR8) in Healthy Adults. Presented at the 2007 Options for the Control of Influenza VI. Toronto, Canada. June 17-23, 2007.


33

17. Keitel W, Campbell JD, Treanor JJ, Walter E, Patel S. A Phase I-II, Randomized, Controlled, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or with Aluminum Hydroxide to Healthy Adults. Presented at the 2007 Options for the Control of Influenza VI. Toronto, Canada. June 17-23, 2007.

18. Wangisi J, Ecuru J, Okoboi S, Campbell J, King R, Egessa A, Bakanda C, Muramuzi E, Kaharuza F, Malamba S, Moor DM. A 5-year comparison of viral load and CD4 cell count monitoring for ART patients in rural Uganda. CROI March, 2014. Poster 1142, P-X2.

Published Multimedia: 1. Influenza recommendations: TV interview Fox 5 in Washington, DC, October 2001. 2. The threat of anthrax: Radio interview, WRKS 95.1 FM in Baltimore, October 2001. 3. Anthrax vaccines: The Baltimore Sun, November, 2001. 4. Testimony at the Maryland State General Assembly, Committee on Environmental Affairs on

behalf of Maryland Chapter of the American Academy of Pediatrics regarding bill addressing preparation for a catastrophic health emergency such as a bioterror attack; February 12, 2002.

5. Testimony at the Maryland State General Assembly, Committee on Environmental Affairs on behalf of Maryland Chapter of the American Academy of Pediatrics regarding bills addressing establishment of advisory council on immunizations, among others; March 12, 2002.

6. Pediatric Advice for Parents: live TV call-in during Saturday morning news program. WUSA Channel 9 (CBS affiliate in Washington, D.C.) August 3, 2002; August 31, 2002; September 21, 2002, other dates.

7. Opinion on Health and Human Services smallpox vaccine recommendations for first responders: TV interview WJZ Channel 13, Baltimore CBS affiliate. Baltimore, September 4, 2002.

8. Opinion on SARS vaccine development: “SARS vaccine may not come quickly.” The NY Journal News, Gannett Newspapers, Westchester NY. Len Meniace, April 28, 2003.

9. Pediatric Research spokesperson: TV introductory segment for all Maryland Kids Care segments WBAL Channel 11, Baltimore, January, 2003.

10. Opinion on new anthrax vaccine trial, TV interview WJZ Channel 13, Baltimore CBS affiliate. Baltimore, July 22, 2003.

11. Opinion on new anthrax vaccine and methods of informed consent, The Baltimore Sun. Baltimore, July 21, 2003.

12. Opinion on new anthrax vaccine trial, TV interview Channel 4, Washington DC. Baltimore, July 28, 2003.

13. Interview on infectious mononucleosis, The Baltimore Sun, article published Sunday, September 14, 2003.

14. Comments on the Regional Center for Excellence in Biodefense and Emerging Infectious Pathogens Award, TV interview, College Park TV station, September 18, 2003.


34

15. Comments on the Regional Center for Excellence in Biodefense and Emerging Infectious Pathogens Award and anthrax vaccines, TV interview, Med Star, a nationally syndicated distributor of health-related news, September 24, 2003.

16. Interview, Maryland Health Today, a public television produced local program; thirty minute interview on topics of pediatric infections and vaccines. Aired multiple times from January to April, 2004.

17. Multiple news stories and interviews regarding GSK influenza vaccine trial; CNN, 2 Washington D.C. TV stations, 1 Baltimore TV station, local radio, and Baltimore Sun. December, 2004 and January, 2005.

18. Testimony at the Maryland State General Assembly, Committee on Health and Government Operations on behalf of Maryland Chapter of the American Academy of Pediatrics regarding bill addressing banning thimerosal-containing vaccines. February 10, 2005.

19. Testimony at the Maryland State General Assembly, Committee on Health and Government Operations on behalf of Maryland Chapter of the American Academy of Pediatrics regarding bill addressing Advisory Commission on Immunizations at the Department of Health and Mental Hygiene. February 10, 2005.

20. Interview regarding avian influenza and pandemic preparation through vaccination with comment on encephalitis cases in Vietnam; Healthday.com, reporter Mr. Edelson, distributed to various media. February 16, 2005.

21. Testimony at the Maryland State General Assembly, Sub-committee on Health on behalf of Maryland Chapter of the American Academy of Pediatrics, scientific evidence on risk of thimerosal-containing vaccines. February 22, 2005.

22. Multiple interviews regarding avian influenza vaccine trial and other issues of avian influenza, including local TV news, local radio news, the Canadian Broadcasting Corporation, Baltimore Sun, Voice of America, National Geographic, Getty Images, Kansas City Star, Scranton News, Health Day, Reuters, Capitol News Agency, LA Times, Washington Post, WYPR (NPR), Tokyo Broadcasting Corporation, CNBC, WTOP radio in Washington, D.C., CNBC, NPR All Things Considered, and others. March-November, 2005.

23. National Live Radio Interview on distribution of H2N2 influenza virus for proficiency testing, Fox Radio, The Tony Snow Show, April 13, 2005.

24. Interviews on childhood meningitis for featured story in Baltimore Magazine, published in the October, 2005 issue.

25. Interview on clinical research subjects, particularly women, and their reasons for volunteering. For Elle magazine, October 2005 issue.

26. Testimony at the Maryland State General Assembly and State Senate on behalf of Maryland Chapter of the American Academy of Pediatrics and the University of Maryland, Baltimore, regarding the scientific evidence on risk of thimerosal-containing vaccines. February 22, 2006.

27. Multiple interviews regarding adjuvanted avian influenza trials including local TV news stations, Baltimore Sun, and others. March, 2006.

28. Participant, Press Conference regarding CDC award to the city of Baltimore on being the US city with the highest proportion of young children fully vaccinated. I represented the MD


35

Chapter of the American Academy of Pediatrics. Eastern Health Clinic, March 6, 2006. 29. Interview on new generation anthrax vaccines, Baltimore Business Journal, November, 2006. 30. Interview on avian influenza vaccine progress, Associated Press, November 2006. 31. Interview on use of RSV challenge model for novel therapeutic anti-viral, Boston Globe,

November 2006. 32. Interview on multiple cases of infant botulism, Baltimore Sun, January 2007. 33. Interview on implementation of Gardasil, the newly licensed vaccine against Human

Papilloma Virus, The Examiner, March 2, 2007. 34. Interview on Nodding Syndrome in the north of Uganda and recent findings, Al Jazeera,

November 2011. 35. Camtasias: I produced educational videos to teach IRB members how to perform protocol

reviews adhering to federal, state, and local regulations and using our institutional online submission program. 2014

36. Interview on Ebola vaccines and mandatory quarantine, CNN Headline News, October 25, 2014.

37. Interview, Ebola vaccines and diagnostics, WJZ Baltimore 11 pm news, October 27, 2014. 38. Interview, Ebola vaccines, Canadian Television (CTV), October 29, 2014 39. Interview, Ebola vaccines, Mother Jones, October 29, 2014 40. Interview, Ebola vaccines, The Economist, October 30, 2014 Major Invited Speeches Baltimore 1. Campbell JD. “Diseases From Things That Bite and Scratch (Cat Scratch and Rabies)” Given at Maryland Cares Third Annual Pediatric Conference, University of Maryland, February 23, 1999. 2. Campbell JD. “Update on Tick-borne Diseases (Lyme, Ehrlichia, RMSF, Tick Paralysis)” Given at the 23rd Annual Meeting of the Maryland Chapter of the American Academy of Pediatrics. Linthicum, MD September 28, 2002. 3. Campbell JD. “Anthrax and Smallpox: The Diseases and Vaccines” Given at the Joint Meeting of the Baltimore County Bar Association and Medical Association. The Old Courthouse, Towson, MD. October 17, 2002. 4. Campbell JD. “Smallpox and Anthrax: A Primer for Clinicians” Grand Rounds, Pediatrics Department, Mercy Hospital, Baltimore, MD. January 31, 2003. 5. Campbell JD. “Vaccines for the New Millennium” Annual Practical Pediatrics Program at Harbor Hospital. Baltimore, MD, May 16, 2003. 6. Campbell JD. “Update on the Pediatric Vaccine Schedule” Pediatric Grand Rounds, Franklin Square Hospital, Baltimore, MD, August 12, 2003. 7. Campbell JD. “Infectious Diseases in the Children of Bamako, Mali West Africa” Pediatric Grand Rounds, University of Maryland Hospital for Children, October 30, 2003. 8. Campbell JD. “S. pneumoniae in the Conjugate Vaccine Era” Annual Meeting of the


36

Maryland Emerging Infectious Pathogens/Active Bacterial Core Surveillance Program, Linthicum, MD, May 3, 2004. 9. Campbell, JD. “What’s New in Childhood Vaccines in 2005?” Annual Meeting of the Nurse Practitioners Association (NAPNAP), Columbia, MD, November 3, 2005. 10. Campbell, JD. “Tick-Borne Diseases” Grand Rounds for the Emergency Departments of Union Memorial and Franklin Square Hospitals, Baltimore, MD November 11, 2005. 11. Campbell JD. “Avian Influenza Vaccines” presented at “Avian Flu: What Can We Do?” a multidisciplinary meeting of scientists, clinicians, and policymakers. Hosted by the Center for Homeland Security, University of Maryland School of Law. January 13, 2006. 12. Campbell JD. “Investigator Responsibilities: Translating GCPs into Real Research” University of Medicine School of Medicine course to fulfill participant requirements for GCP training. University of Maryland School of Medicine, Baltimore, MD. March 24, 2006. 13. Campbell JD. “Avian Influenza and Vaccines; A Primer for the Public” presented to the Chinese American Society of Greater Washington, D.C. March 25, 2006. 14. Campbell JD. “Rotavirus: The Virus, The Illness, The Vaccine” presented at Pediatric Grand Rounds to the Department of Pediatrics, Mercy Medical Center, Baltimore MD. April 28, 2006. 15. Campbell, JD. “Pandemic Influenza” presented at the Annual Meeting of the Public Employees Safety Association (PESA) of Maryland, August 4, 2006. 16. Campbell JD. “The Importance of Vaccines” presented at Mini Med School, an annual lecture series for members of the Baltimore community. University of Maryland School of Medicine, Baltimore, MD. September 20, 2006. 17. Campbell JD. “Rotavirus: The Virus, The Illness, The Vaccine” presented at Pediatric Grand Rounds to the Department of Pediatrics, The Children’s Hospital at Sinai, Baltimore MD. February 13, 2007. 18. Campbell JD. “The New Rotavirus Vaccines” presented at Pediatric Grand Rounds to the Department of Pediatrics, University of Maryland School of Medicine, Baltimore MD. March 1, 2007. 19. Campbell JD. “HIV, Marburg Hemorrhagic Fever, Schisotosomiasis, and Nodding Syndrome in Uganda: 2007-2012.” Pediatric Grand Rounds, Mercy Hospital, Baltimore, MD. November 22, 2013. 20. Campbell JD, Manabe YC. “Top Ten Tropical Medicine Stories, Uganda, 2007-12.” The Tropical Medicine Dinner Club of Baltimore/Washington. April 3, 2014. 21. Campbell JD. “International Research: Ethical and Regulatory Considerations.” Human Research Protections Office IRB Grand Rounds. University of Maryland Baltimore . July 21, 2014. 22. Campbell JD. “Good Clinical Practices: A Simple Guide.” Human Research Protections Office IRB Grand Rounds. University of Maryland Baltimore. September 11, 2014. 23. Campbell JD. “Ebola” Grand Rounds, Department of Medicine, University of Maryland School of Medicine. September 17, 2014. 24. Campbell JD. “Ebola” Grand Rounds, Department of Pediatrics, University of Maryland School of Medicine. October 30, 2014. 25. Campbell JD. “Ebola” Grand Rounds, Department of Medicine, Greater Baltimore Medical


37

Center (GBMC). October 31, 2014. 26. Campbell JD. “Ebola” Grand Rounds, Department of Pediatrics, St. Agnes Medical Center, Baltimore, MD. January 23, 2015. 27. Campbell JD. “Pediatric Clinical Research- Ethical and Regulatory Review.” Human Research Protections Office IRB Grand Rounds. University of Maryland Baltimore. March 23, 2015. National 1. Campbell JD. “Vaccine-preventable Diseases in the Children of Bamako, Mali” Given to the Infectious Disease Divisions of the Departments of Pediatrics and Internal Medicine as visiting professor, Dartmouth Medical College and Dartmouth-Hitchcock Medical Center, Hanover, NH; June 15, 2004. 2. Campbell JD. “Anthrax Vaccines: A Phase I Trial of Recombinant Protective Antigen” Given at “Terrorism and Trauma: A Transatlantic Perspective,” a conference jointly sponsored by the President of the University of Maryland Baltimore and the Royal Society of Medicine. September 22, 2004. 3. Campbell JD. “Epidemiology of Group A Streptococcus in Bamako, Mali” Given at the Annual Meeting of The Lancefield Society, Boston, MA; October 1, 2004. 4. Campbell JD. “Phase I Trial of Recombinant Protective Antigen Anthrax Vaccine” Given at the 42nd Annual Meeting of the Infectious Disease Society of America (IDSA), Boston, MA; October 2, 2004. 5. Campbell JD. “Avian Influenza: Pandemic Preparedness” Given at the 32nd Annual International Meeting of the Association for Professionals in Infection Control and Epidemiology (APIC), Baltimore Convention Center, Baltimore, MD; June 20-23, 2005. 6. Campbell JD. “Immunization Update 2005” Given at the annual regional meeting of the National Association of Nurse Practitioners, Columbia, MD; November 3, 2005. 7. Campbell JD. “Avian Influenza Vaccines: Update on Development” Presented at the Plenary Session of the 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America, Baltimore, MD. April 12-16, 2007. 8. Campbell JD. “Pediatric Infectious Diseases Review” given at PREP The Course, a board review course and pediatric refresher course sponsored by the American Academy of Pediatrics. Denver, CO June 23-26, 2006 and Minneapolis, MN June 22-25, 2007. 9. Campbell JD. “Avian Influenza Vaccines: An Update for Pediatricians” Presented at the Hot Topics in Vaccines Session of the Annual Pediatric Academic Societies Meeting Toronto, Canada. May 5-8, 2007. International 1. Campbell JD. “Enteric Pathogen Challenges in Human Volunteers at the Center for Vaccine Development” WHO Workshop on Hazard Characterization of Pathogens in Food and Water, June 13-17, 2000, Bilthoven, The Netherlands. 2. Campbell JD. “Intranasal Vaccination against Measles” at the Fourth Meeting of the Product Development Group of the World Health Organization for Aerosol Measles Vaccine. Baltimore,


38

June 19-20, 2003. 3. Campbell JD. “Intranasal Vaccination against Measles; the Trial in Santiago, Chile” at the Seventh Meeting of the Product Development Group of the World Health Organization for Aerosol Measles Vaccine. Geneva, Switzerland, November 7-8, 2005. 4. Campbell JD. “Inactivated H5N1 Avian Influenza Vaccine” presented at The Lancet Asia Medical Forum 2006: Preparing for Pandemic Influenza; Suntec Singapore, May 3-4, 2006. Proffered Communications Guam 1. Campbell JD. “Seafood Sickness” Combined Conference, Naval Hospital Guam, October 11, 1994. 2. Campbell JD. “Diphtheria: Disease and Vaccine” Naval Hospital Guam, February 1, 1995. 3. Campbell JD. “Tetanus: Disease and Vaccine” Naval Hospital Guam, March 5, 1995. 4. Campbell JD. “Pertussis: Disease and Vaccine. Whole Cell versus Acellular” Naval Hospital Guam, April 10, 1995. 5. Campbell JD. “Polio: Disease and Vaccine. IPV versus OPV” Naval Hospital Guam, June 20, 1995. 6. Campbell JD. “Measles: Vaccine and Disease; the Recent Epidemic” Naval Hospital Guam, August 11, 1995. 7. Campbell JD. “Mumps: Vaccine and Disease” Naval Hospital Guam, September 12, 1995. 8. Campbell JD. “Haemophilus: Conjugate Vaccine and Disease” Naval Hospital Guam, September 30, 1995. 9. Campbell JD. “Rubella: Vaccine and Disease. Congenital Rubella Syndrome” Naval Hospital Guam, October 6, 1995. 10. Campbell JD. “Current Management of Anaphylaxis in Pediatrics” Naval Hospital Guam, November 7, 1995. 11. Campbell JD. “Primer on Neonatal Hematology” Naval Hospital Guam, November 16, 1995. 12. Campbell JD. “Viral Hepatitis: Vaccines and Diseases” Naval Hospital Guam, March 2, 1996. 13. Campbell JD. “Status Asthmaticus” The Doctors’ Clinic, Guam, March 21, 1996. Micronesia 1. Campbell JD. “Current Management of Seizures” Kosrae Medical Center, July 10, 1995. 2. Campbell JD. “Current Management of Meningitis” Kosrae Medical Center, September 18,


39

1995. National Naval Medical Center 1. Campbell JD. “Immunization Update 1997" National Naval Medical Center, 1997. 2. Campbell JD. “Advances in Genetics of Immunodeficiencies” National Naval Medical Center, 1997. 3. Campbell JD. “Top Ten Pediatric Articles: 1997.” National Naval Medical Center, 1997. 4. Campbell JD. “Immunization Update 1998" National Naval Medical Center, 1998. 5. Campbell JD. Lecture Series on each health maintenance visit for infants and children. Given every month for 10 months, National Naval Medical Center, 1997-8. 6. Campbell JD. “Top Ten Pediatric Articles: 1998.” National Naval Medical Center, 1998. 7. Campbell JD. “Infant Botulism” National Naval Medical Center, 1998. University of Maryland School of Medicine 1. Campbell JD. “Current Management of Meningitis” Noon Conference, University of Maryland, August 1998. 2. Campbell JD. “Congenital Toxoplasmosis” Noon Conference, University of Maryland, 1999. 3. Campbell JD. “Congenital Syphilis” Noon Conference, University of Maryland, 1999. 4. Campbell JD. “Cat Scratch Disease” Noon Conference, University of Maryland, 1999. 5. Campbell JD. “Infant Botulism” Microbiology “Plate Rounds,” University of Maryland, June 24, 1999. 6. Campbell JD. “Neonatal Herpes Simplex Infection” Morbidity and Mortality Conference, University of Maryland, 1999. 7. Campbell JD. “Immunization Update 1999.” Noon Conference, University of Maryland, July 30, 1999. 8. Campbell JD. “Current Management of Meningitis.” Noon Conference, University of Maryland, August 30, 1999. 9. Campbell JD. “Rabies Update.” Noon Conference, University of Maryland, September 22, 1999. 10. Campbell JD. “Congenital Syphilis.” Noon Conference, University of Maryland, January 7, 2000. 11. Campbell JD. “The Use of the Laboratory in Clinical Infectious Diseases” Noon Conference, University of Maryland, April 7, 2000. 12. Campbell JD. “What Every Pediatric Resident Should Know About Vaccines.” Noon Conference, University of Maryland, July 26, 2000. 13. Campbell JD. “Recent Data on Pneumococcal Conjugate Vaccine Efficacy and Cold-Adapted Influenza Vaccine in Children.” Combined Conference: Adult and Pediatric Infectious Diseases, University of Maryland, November 27, 2000. 14. Campbell JD. “The Epidemiologic Evidence Supporting an Association Between MMR Vaccine and Pervasive Development Disorder.” Department of Epidemiology and Preventive Medicine, University of Maryland, December 18, 2000. 15. Campbell JD. “Influenza: The Basics and New Issues in Treatment and Control.” Noon


40

Conference, University of Maryland, January 12, 2001. 16. Campbell JD. “Protozoan Enteric Pathogens.” Morning Pediatric Conference, University of Maryland, January 26, 2001. 17. Campbell JD. “Rocky Mountain Spotted Fever.” Morning Pediatric Conference, University of Maryland, February 21, 2001. 18. Campbell JD. “Chronic Granulomatous Disease and other Granulocyte Related Diseases.” Morning Pediatric Conference, University of Maryland, March 19, 2001. 19. Campbell JD. “Rabies Update” Noon Conference, University of Maryland, April 11, 2001. 20. Campbell JD. “What Every Resident Should Know about Vaccines” Noon Conference, University of Maryland, July 6, 2001. 21. Campbell JD. “Senior Clinician Rounds: Burkitts Lymphoma Presenting as Empyema” University of Maryland, September 5, 2001. 22. Campbell JD. “Infectious Diarrhea” Noon Conference, University of Maryland, October, 2001. 23. Campbell JD. “Influenza: the disease, its treatment and prevention” Noon Conference, University of Maryland, November, 2001. 24. Campbell JD. “Introduction to the Clinical Microbiology Laboratory” Noon Conference, University of Maryland, February 15, 2002. 25. Campbell JD. “Deadly potpourri: botulism, tetanus, and rabies” Noon Conference, University of Maryland, April 30, 2002. 26. Campbell JD. “What’s Infecting the Children in Bamako, Mali?” CVD Research Seminar, University of Maryland, May 15, 2002. 27. Campbell JD. “Microbiology for Pediatric Housestaff” Noon Conference, University of Maryland, July 29, 2002. 28. Campbell JD. “What’s Infecting the Children in Bamako, Mali? The First 100 Days” CVD Research Seminar, University of Maryland, September 18, 2002. 29. Campbell JD. “BioDefense at the University of Maryland Hospital for Children” Address to the Board of Visitors of the Hospital, University of Maryland, December 10, 2002. 30. Campbell JD. “Vaccines Against Agents of Biowarfare” Noon Conference, University of Maryland, December 10, 2002. 31. Campbell JD. “Pediatric Vaccines for Adult ID Fellows” Board Review Course, University of Maryland, January 10, 2003. 32. Campbell JD. “Traveling MDs: Experiences in Mali, Marshall Islands, and Micronesia” Medical Student International Health Interest Group, University of Maryland, January 21, 2003. 33. Campbell JD. “Anthrax Vaccines” Project Medical Education, a School of Medicine sponsored program to inform local, state, and federal legislators and their staff on the medical school, University of Maryland, November 21, 2003. 34. Campbell JD. “Clinical Development Plan for Novel Measles Vaccines” presented at the joint University of Maryland-Johns Hopkins University symposium on Advances in Measles Vaccines. University of Maryland School of Medicine, February 24, 2004. 35. Campbell JD. “Introduction to Clinical Microbiology” Pediatric Housestaff Core Conference. University of Maryland, August 3, 2004.


41

36. Campbell JD. “Epidemics, Pandemics, and Vaccines: Influenza H5N1 Virus” Center for Vaccine Development Clinical Conference. University of Maryland, August 6, 2004. 37. Campbell, JD. “Botulism, Rabies, Tetanus: An Update and Review” presented to the Adult and Pediatric Infectious Disease Fellows at their Board Review Core Conference. University of Maryland, October 8, 2004. 38. Campbell. JD. “Early Clinical Evaluation of Vaccines: Phase I and II Trials” presented in the Vaccinology course in the Department of Epidemiology and Preventive Medicine. University of Maryland School of Medicine, February 9, 2005. 39. Campbell, JD. “Avian Influenza” presented to the General Clinical Research Center of the University of Maryland School of Medicine in preparation for a clinical vaccine trial. February 16, 2005. 40. Campbell, JD. “Microbiology for Pediatric Housestaff with a Tour of the Clinical Microbiology Laboratory” presented to the Pediatrics housestaff as a core residency lecture, University of Maryland. July 13, 2005. 41. Campbell, JD. “Influenza, A Review” presented to Adult and Pediatric Infectious Disease Fellows, Board review Course, University of Maryland, March 31, 2006. 42. Campbell, JD. “Infant Botulism and Rabies” presented to Pediatric Residents and Students, University of Maryland, July 31, 2006. 43. Campbell, JD. “Tetanus: Clinical Issues and Vaccination” presented to Pediatric Residents and Students, University of Maryland, August 2, 2006. 44. Campbell, JD. “Influenza: Update for 2006” presented to Pediatric Residents and Students, University of Maryland, August 7, 2006. 45. Campbell, JD. “Board Review: Otitis, Mycoplasma, EBV, Vaccination” presented to Pediatric ID Fellow, rotating Pediatric Resident and visiting student, University of Maryland, August 10, 2006. 46. Campbell, JD. “HIV, Marburg Hemorrhagic Fever, Schistosomiasis, and Nodding Syndrome in Uganda: 2007-2012.” Presented to the Global Health Track participants in the Pediatric and Med/Peds Residency Programs, University of Maryland School of Medicine, April 4, 2014. 47. Campbell, JD. “Infectious Diseases in Uganda.” Presented to the University of Maryland School of Medicine Global Health student interest group (about 20 students). February 24, 2015. 48. Campbell, JD. “Vaccines: How they work and the historical impact.” Presented to the Pediatric Forum of the University of Maryland School of Pharmacy in conjunction with speakers from the School of Pharmacy and the vaccine advocacy group Shot@Life with the UN Foundation. (~40 students) April 6, 2015. Baltimore, Maryland Region 1. Campbell, JD. “Update on Immunizations: Sept 2006—Rotavirus, Human Papilloma Virus, Varicella, Influenza, and Hepatitis A” Presented to Annapolis Pediatrics, September 14, 2006. 2. Campbell, JD. “Update on Immunizations: March 2007 —New Meningococcal Conjugate Vaccines, Rotateq, Gardasil, Avian Influenza, and Cytomegalovirus” Presented to Annapolis Pediatrics, March 8, 2007.


42

Uganda 1. Campbell, JD. “Introduction to the University of Washington/Gates Foundation sponsored clinical trial on pre-exposure prophylaxis of HIV-negative partners in discordant couple relationships: tenofovir vs Truvada.” Presented to the staff of CDC-Uganda Tororo field site, November 1, 2007. 2. Campbell, JD. “Research 101: How to write manuscripts and abstracts.” Presented to the staff of CDC-PrEP teams, Mbale and Tororo and selected members of The AIDS Support Organization (TASO), February, 2008. 3. Campbell, JD. “Mitochondrial Toxicities following antiretroviral therapy” Presented to the Home Based AIDS Care Program clinical staff. January, 2008. 4. Campbell, JD. “Progressive Multifocal Leukoencephalopathy- Can it mimic stroke?” Presented to the Home Based AIDS Care Program clinical staff. February, 2008. 5. Campbell, JD. “Outbreak Investigations: An Overview” Presented to the Epidemiology Branch of CDC Uganda. 29 Nov 2010. 6. Campbell, JD. “Nodding Syndrome” Presented to a Joint Meeting of Kenya, Uganda, and US-based Global Disease Detection representatives at a seminar in Kampala, Uganda. October 2011. 7. Campbell, JD. “Pre-Exposure Prophylaxis and Early Treatment of the Infected Partner in Serodiscordant Couples” presented at the Makerere University/ Johns Hopkins University/London School of Hygiene and Tropical Medicine as part of the Diploma in Tropical Medicine and Hygiene (DTMH) course, Kampala, Uganda. November 2011.

james daniel campbell, m.d., m.s. - university of maryland ... · james daniel campbell, m.d., m.s....

Documents